RU2007113811A - Способ получения оптически активных производных амина - Google Patents
Способ получения оптически активных производных амина Download PDFInfo
- Publication number
- RU2007113811A RU2007113811A RU2007113811/04A RU2007113811A RU2007113811A RU 2007113811 A RU2007113811 A RU 2007113811A RU 2007113811/04 A RU2007113811/04 A RU 2007113811/04A RU 2007113811 A RU2007113811 A RU 2007113811A RU 2007113811 A RU2007113811 A RU 2007113811A
- Authority
- RU
- Russia
- Prior art keywords
- weight
- furan
- tetrahydro
- indeno
- content
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/80—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Emergency Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Furan Compounds (AREA)
Claims (17)
1. Способ получения (S)-2-(1,6,7,8-тетрагидро-2H-индено[5,4-b]фуран-8-ил)этиламина или его соли, который включает стадию (i): стадию асимметрического восстановления (E)-2-(1,6,7,8-тетрагидро-2H-индено[5,4-b]фуран-8-илиден)этиламина или его соли на катализаторе, и стадию (ii): стадию каталитического восстановления реакционного продукта, полученного на стадии (i), при температуре реакции от 40°C до 100°C и pH от 3 до 9 на катализаторе.
2. Способ по п.1, в котором температура реакции на стадии (ii) составляет от 50°C до 70°C.
3. Способ по п.1, в котором pH на стадии (ii) составляет от 5 до 7.
4. Способ по п.1, в котором катализатором на стадии (i) является Ru-BINAF катализатор.
5. Способ по п.1, в котором катализатором на стадии (ii) является Pd-C катализатор.
6. Способ получения кристаллов (S)-N-[2-(1,6,7,8-тетрагидро-2H-индено[5,4-b]фуран-8-ил)этил]пропионамида, включающий стадию (a): стадию пропионилирования аминогруппы (S)-2-(1,6,7,8-тетрагидро-2H-индено[5,4-b]фуран-8-ил)этиламина или его соли, полученного способом по п.1, и стадию (b): стадию кристаллизации путем добавления водного растворителя к реакционному раствору, полученному на стадии (a).
7. Кристаллы (S)-N-[2-(1,6,7,8-тетрагидро-2H-индено[5,4-b]фуран-8-ил)этил]пропионамида, в которых содержание каждого из соединений, представленных следующими формулами (I), (II), (III) и (IV), составляет 0,15% по массе или менее, и суммарное содержание соединений, представленных следующими формулами (I) -(IV), составляет 0,2% по массе или менее.
8. Кристаллы (S)-N-[2-(1,6,7,8-тетрагидро-2H-индено[5,4-b]фуран-8-ил)этил]пропионамида, в которых содержание каждого из соединений, представленных следующими формулами (I), (II), (III) и (IV), составляет 0,15% по массе или менее, и содержание соединения, представленного следующей формулой (II), составляет от 0,02 до 0,15% по массе, и, кроме того, суммарное содержание соединений, представленных следующими формулами (I)-(IV), составляет 0,2% по массе или менее.
9. Кристаллы по пп. 7 и 8, в которых содержание соединения, представленного формулой (I), составляет 0,10% по массе или менее.
10. Композиция, включающая (S)-N-[2-(1,6,7,8-тетрагидро-2H-индено[5,4-b]фуран-8-ил)этил]пропионамид и соединения, представленные следующими формулами (I), (II), (III) и (IV), в которой относительно 100 частей по массе (S)-N-[2-(i,6,7,8-тетрагидро-2H-индено[5,4-b]фуран-8-ил)этил]пропионамида, содержание каждого из соединений, представленных следующими формулами (I), (II), (III) и (IV), составляет от 0 до 0,15 частей по массе, и суммарное содержание соединений, представленных следующими формулами (I)-(IV), составляет от 0 до 0,2 частей по массе.
11. Композиция, включающая (S)-N-[2-(1,6,7,8-тетрагидро-2H-индено[5,4-b]фуран-8-ил)этил]пропионамид и соединения, представленные следующими формулами (I), (II), (III) и (IV), в которой относительно 100 частей по массе (S)-N-[2-(1,6,7,8-тетрагидро-2H-индено[5,4-b]фуран-8-ил)этил]пропионамида, содержание каждого из соединений, представленных следующими формулами (I), (III) и (IV), составляет от 0 до 0,15 частей по массе, и содержание соединения, представленного следующей формулой (II), составляет от 0,02 до 0,15 частей по массе, и дополнительно суммарное содержание соединений, представленных следующими формулами (I)-(IV), составляет от 0 до 0,2 частей по массе.
13. Кристаллы по п.7 или композиция по п.10, которую получают в промышленном масштабе.
14. Способ получения 1,2,6,7-тетрагидро-8H-индена[5,4-b]фуран-8-она, включающий стадию восстановления 4,5-дибром-1,2,6,7-тетрагидро-8H-индено[5,4-b]фуран-8-она на Pd-C катализаторе при условии:
давление водорода (МПа)>-0,02·суммарный объемный коэффициент массопередачи газ-жидкость (1/ч)+0,43.
15. Применение кристаллов по п.7 для получения профилактического или терапевтического средства при нарушении сна.
16. Композиция по п.10, которая является профилактическим или терапевтическим средством при нарушении сна.
17. Способ предотвращения или лечения нарушения сна, включающий введение кристаллов по п.8 или композиции по п.10.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004265307 | 2004-09-13 | ||
JP2004-265307 | 2004-09-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2007113811A true RU2007113811A (ru) | 2008-10-20 |
RU2385318C2 RU2385318C2 (ru) | 2010-03-27 |
Family
ID=36059992
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2007113811/04A RU2385318C2 (ru) | 2004-09-13 | 2005-09-12 | Способ получения оптически активных производных амина |
Country Status (31)
Country | Link |
---|---|
US (4) | US8097737B2 (ru) |
EP (2) | EP2537842A1 (ru) |
JP (2) | JP5127228B2 (ru) |
KR (1) | KR101298335B1 (ru) |
CN (2) | CN102516211A (ru) |
AR (1) | AR050737A1 (ru) |
AU (1) | AU2005283521B2 (ru) |
BR (1) | BRPI0515170A (ru) |
CA (2) | CA2579121C (ru) |
CR (2) | CR8975A (ru) |
EC (1) | ECSP077317A (ru) |
ES (1) | ES2485890T3 (ru) |
GE (1) | GEP20094725B (ru) |
GT (2) | GT200500257AA (ru) |
HN (1) | HN2005000548A (ru) |
IL (2) | IL181462A (ru) |
MA (1) | MA28855B1 (ru) |
MX (1) | MX2007002822A (ru) |
MY (2) | MY147822A (ru) |
NO (1) | NO20071866L (ru) |
NZ (1) | NZ553562A (ru) |
PA (1) | PA8645701A1 (ru) |
PE (3) | PE20060662A1 (ru) |
RU (1) | RU2385318C2 (ru) |
SA (1) | SA05260347A (ru) |
SG (1) | SG151330A1 (ru) |
TW (1) | TWI400220B (ru) |
UA (1) | UA95598C2 (ru) |
UY (1) | UY29118A1 (ru) |
WO (1) | WO2006030739A1 (ru) |
ZA (1) | ZA200701724B (ru) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5450056B2 (ja) * | 2007-03-19 | 2014-03-26 | 武田薬品工業株式会社 | アリルアミン不斉水素化法 |
WO2008150953A1 (en) * | 2007-05-30 | 2008-12-11 | Dr. Reddy's Laboratories Ltd. | Process of making ramelteon and related substances |
WO2008151170A2 (en) * | 2007-05-31 | 2008-12-11 | Teva Pharmaceutical Industries Ltd. | Process for the synthesis of ramelteon and its intermediates |
WO2009060318A2 (en) * | 2007-07-12 | 2009-05-14 | Teva Pharmaceutical Industries Ltd. | Polymorphic forms of ramelteon and processes for preparation thereof |
CN101531647B (zh) * | 2008-03-13 | 2012-10-31 | 常州亚邦制药有限公司 | (±)-2-(1,6,7,8-四氢-2H-茚并[5,4-b]呋喃-8-基)乙胺的拆分方法 |
JP2011528012A (ja) * | 2008-07-14 | 2011-11-10 | レツク・フアーマシユーテイカルズ・デー・デー | ラメルテオンの調製における中間体としての6,7−ジヒドロ−1h−インデノ[5,4−b]フラン−8(2h)−オンの合成 |
US20100152468A1 (en) * | 2008-10-16 | 2010-06-17 | Teva Pharmaceutical Industries Ltd. | Process for the synthesis of ramelteon and its intermediates |
EP2396309A1 (en) | 2009-02-12 | 2011-12-21 | LEK Pharmaceuticals d.d. | Synthesis of (s)-n-ý2-(1,6,7,8-tetrahydro-2h-indeno-ý5,4-b¨furan-8-yl)ethyl¨propionamide |
CN101824012B (zh) * | 2009-03-02 | 2011-12-07 | 四川大学 | 2-(1,6,7,8-四氢-2H-茚并-[5,4-b]呋喃-8-基)乙腈及其制备方法和用途 |
WO2010103553A1 (en) | 2009-03-10 | 2010-09-16 | Industriale Chimica S.R.L. | Process for the preparation of ramelteon |
EP2243775A1 (en) | 2009-04-07 | 2010-10-27 | LEK Pharmaceuticals d.d. | Synthesis of 1-(2,3-Dihydrobenzofuran-4-YL)ethanone as intermediate in the preparation of ramelteon |
WO2011027323A1 (en) | 2009-09-03 | 2011-03-10 | Ranbaxy Laboratories Limited | Process for the preparation of ramelteon |
WO2011027319A1 (en) | 2009-09-03 | 2011-03-10 | Ranbaxy Laboratories Limited | Process for the preparation of an intermediate for ramelteon |
CN101665477B (zh) * | 2009-09-21 | 2012-05-09 | 四川大学 | (e)-3-(苯并呋喃-5-基)丙烯酸酯类化合物、其制备方法和用途 |
CN101648931B (zh) * | 2009-09-21 | 2012-05-09 | 四川大学 | 一种3-(2,3-二氢苯并呋喃-5-基)-丙酸的制备方法 |
EP2483258A1 (en) | 2009-09-29 | 2012-08-08 | Lonza Ltd. | Process for preparing 1,2,6,7-tetrahydro-8h-indeno[5,4-b]furan-8-one |
WO2012035303A2 (en) | 2010-09-17 | 2012-03-22 | Cipla Limited Et Al | A novel process for synthesis of ramelteon, and key intermediates for the synthesis of ramelteon |
CN103664849B (zh) * | 2012-08-31 | 2017-03-29 | 上海阳帆医药科技有限公司 | 制备2‑(1,6,7,8‑四氢‑2H‑茚并[5,4‑b]呋喃‑8‑亚基乙胺的方法 |
CN102924410A (zh) * | 2012-10-29 | 2013-02-13 | 华润赛科药业有限责任公司 | 一种雷美替胺的制备方法及其中间体 |
CN103396387A (zh) * | 2013-08-07 | 2013-11-20 | 安徽联创药物化学有限公司 | 雷美替胺中间体的制备方法 |
CN105277628B (zh) * | 2014-07-07 | 2017-05-31 | 南京长澳医药科技有限公司 | 通过高效液相色谱法分离测定雷美替胺及其杂质的方法 |
CN104402848B (zh) * | 2014-09-22 | 2017-02-08 | 珠海联邦制药股份有限公司 | 雷美替胺中的杂质化合物的制备方法及制备的标准品 |
CN105622557B (zh) * | 2014-11-05 | 2018-12-04 | 上海医药工业研究院 | 雷美替胺中间体及其制备方法 |
KR102359229B1 (ko) | 2020-04-16 | 2022-02-07 | 제이투에이치바이오텍 (주) | 라멜테온의 제조 방법 및 이러한 제조 방법에 이용되는 중간체 화합물 |
CN115477628A (zh) * | 2022-10-17 | 2022-12-16 | 江苏海悦康医药科技有限公司 | 一种雷美替胺二聚体的合成方法 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0757758B2 (ja) | 1988-10-24 | 1995-06-21 | 高砂香料工業株式会社 | ルテニウム―ホスフィン錯体 |
US6060503A (en) | 1991-12-02 | 2000-05-09 | Endorecherche, Inc. | Benzopyran-containing compounds and method for their use |
PT812835E (pt) | 1995-03-02 | 2001-08-30 | Sankyo Co | Derivados opticamente activos de tiazolidinona |
EP1199304A1 (en) * | 1997-03-05 | 2002-04-24 | Takeda Chemical Industries, Ltd. | Bicyclic compounds and pharmaceutical composition containing tricyclic compound for treating or preventing sleep disorders |
US6034239A (en) * | 1996-03-08 | 2000-03-07 | Takeda Chemical Industries, Ltd. | Tricyclic compounds, their production and use |
JP2884153B2 (ja) | 1996-03-08 | 1999-04-19 | 武田薬品工業株式会社 | 三環性化合物、その製造法および剤 |
JP4242940B2 (ja) | 1997-02-13 | 2009-03-25 | 高砂香料工業株式会社 | 光学活性アミン誘導体の製造法 |
JP4081161B2 (ja) * | 1997-09-05 | 2008-04-23 | 武田薬品工業株式会社 | 光学活性化合物の製造法 |
JP3509637B2 (ja) * | 1998-06-09 | 2004-03-22 | 武田薬品工業株式会社 | 睡眠障害予防治療剤 |
CA2332521C (en) * | 1998-06-09 | 2009-02-10 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition for treating or preventing sleep disorders |
CA2650698C (en) * | 2000-11-17 | 2013-05-28 | Takeda Pharmaceutical Company Limited | Copolyvidone-containing preparation |
JP3633895B2 (ja) * | 2000-11-17 | 2005-03-30 | 武田薬品工業株式会社 | コポリビドン含有製剤 |
-
2005
- 2005-09-06 TW TW094130493A patent/TWI400220B/zh not_active IP Right Cessation
- 2005-09-09 PE PE2005001052A patent/PE20060662A1/es not_active Application Discontinuation
- 2005-09-09 PE PE2012001990A patent/PE20130154A1/es not_active Application Discontinuation
- 2005-09-09 PE PE2008001369A patent/PE20081390A1/es not_active Application Discontinuation
- 2005-09-12 RU RU2007113811/04A patent/RU2385318C2/ru not_active IP Right Cessation
- 2005-09-12 EP EP12182935A patent/EP2537842A1/en not_active Withdrawn
- 2005-09-12 NZ NZ553562A patent/NZ553562A/en not_active IP Right Cessation
- 2005-09-12 SG SG200902222-9A patent/SG151330A1/en unknown
- 2005-09-12 EP EP05782085.4A patent/EP1792899B1/en active Active
- 2005-09-12 MY MYPI20054286A patent/MY147822A/en unknown
- 2005-09-12 WO PCT/JP2005/016761 patent/WO2006030739A1/ja active Application Filing
- 2005-09-12 CN CN201110304598XA patent/CN102516211A/zh active Pending
- 2005-09-12 CA CA2579121A patent/CA2579121C/en active Active
- 2005-09-12 CA CA2764314A patent/CA2764314C/en active Active
- 2005-09-12 US US11/662,684 patent/US8097737B2/en active Active
- 2005-09-12 UA UAA200702582A patent/UA95598C2/ru unknown
- 2005-09-12 CN CN2005800388478A patent/CN101056867B/zh active Active
- 2005-09-12 MY MYPI20091231A patent/MY158073A/en unknown
- 2005-09-12 JP JP2006535875A patent/JP5127228B2/ja active Active
- 2005-09-12 AR ARP050103792A patent/AR050737A1/es not_active Application Discontinuation
- 2005-09-12 BR BRPI0515170-8A patent/BRPI0515170A/pt not_active IP Right Cessation
- 2005-09-12 MX MX2007002822A patent/MX2007002822A/es active IP Right Grant
- 2005-09-12 ES ES05782085.4T patent/ES2485890T3/es active Active
- 2005-09-12 GE GEAP20059926A patent/GEP20094725B/en unknown
- 2005-09-12 KR KR1020077005754A patent/KR101298335B1/ko not_active IP Right Cessation
- 2005-09-12 AU AU2005283521A patent/AU2005283521B2/en not_active Ceased
- 2005-09-12 ZA ZA200701724A patent/ZA200701724B/xx unknown
- 2005-09-13 HN HN2005000548A patent/HN2005000548A/es unknown
- 2005-09-13 UY UY29118A patent/UY29118A1/es not_active Application Discontinuation
- 2005-09-13 GT GT200500257AK patent/GT200500257AA/es unknown
- 2005-09-13 GT GT200500257A patent/GT200500257A/es unknown
- 2005-09-13 PA PA20058645701A patent/PA8645701A1/es unknown
- 2005-11-08 SA SA05260347A patent/SA05260347A/ar unknown
-
2007
- 2007-02-20 IL IL181462A patent/IL181462A/en not_active IP Right Cessation
- 2007-03-06 CR CR8975A patent/CR8975A/es unknown
- 2007-03-09 MA MA29745A patent/MA28855B1/fr unknown
- 2007-03-13 EC EC2007007317A patent/ECSP077317A/es unknown
- 2007-04-12 NO NO20071866A patent/NO20071866L/no not_active Application Discontinuation
-
2010
- 2010-08-09 IL IL207510A patent/IL207510A/en not_active IP Right Cessation
-
2011
- 2011-12-14 US US13/325,946 patent/US20120088826A1/en not_active Abandoned
- 2011-12-21 CR CR20110698A patent/CR20110698A/es unknown
-
2012
- 2012-01-26 JP JP2012014435A patent/JP5615304B2/ja active Active
- 2012-08-29 US US13/597,361 patent/US8609871B2/en active Active
-
2013
- 2013-11-13 US US14/079,607 patent/US20140066499A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2007113811A (ru) | Способ получения оптически активных производных амина | |
CA2571816A1 (en) | Absorbent for separation of carbon dioxide | |
BR122012009489B8 (pt) | processo para produzir 2-etóxi-1-{[2-(5-oxo-4,5-diidro-1,2,4-oxadiazol-3-il)bifenil-4-il]metil}-1h-benzimidazol-7-carboxilato de (5-metil-2-oxo-1,3-dioxol-4-il)metila ou um sal do mesmo, composição farmacéutica, e, uso | |
RU2009102832A (ru) | С-фенил-1-тилоглюцитолы | |
RU2005111969A (ru) | Производные пирролидона в качестве ингибиторов моноаминоксидазы в (мао-в) | |
RU2005104104A (ru) | Производные амида коричной кислоты | |
NO20081675L (no) | Cykliske N-[1,3,4]-tiadiazol-2-yl-benzensulfonamlder, fremgangsmate for fremstilling derav og deres anvendelse som farmasoytika | |
NO20044881L (no) | Acyl-3-karboksyfenylureaderivater, fremstillingsfremgangsmate og anvendelse derav | |
CA2641542A1 (en) | Improved process for producing nitroisourea derivatives | |
NO20073330L (no) | Sulfanylsubstituerte fenylmetanoner som glycintransportor 1 (glyt-1) inhibitorer for behandling av nevrologiske og nevropsykiatriske forstyrrelser | |
HUP0301632A2 (en) | Composition and compound based on metal and acid salt(s) having a sulphonyl group borne by a perhalogenated carbon and their use as lewis acid | |
JP2008524327A5 (ru) | ||
TW541294B (en) | Process for producing aminomethyl-heterocyclic derivative | |
CN108101796B (zh) | 一种叔胺类化合物及其用途 | |
JP2004538278A5 (ru) | ||
MA28030A1 (fr) | Procede de purification | |
NO20023577D0 (no) | Fremgangsmåte for fremstilling av acetyl-amidinofenylalanyl- cykloheksylglycyl-pyridinioalaninamider | |
CN105001102B (zh) | 手性拆分制备单一构型氟西汀的方法 | |
CA2498285A1 (en) | Aroyl-piperidine derivatives | |
HUP0001727A2 (hu) | Új 1-aza-2-alkil-6-aril-cikloalkán-származékok, eljárás előállításukra és ezeket tartalmazó gyógyászati készítmények | |
Niu | Design, Synthesis and Biological Activity of α-Acylaminoamide Derivatives as Influenza Nucleoprotein Inhibitors | |
JPS63222153A (ja) | 新規α−シアノケイ皮酸アミド誘導体 | |
JP4102569B2 (ja) | アミノ酸アミドの製造方法 | |
CN104327007B (zh) | 3,4,5-三取代噁唑烷酮类化合物及其制备方法 | |
KR960700050A (ko) | 2,3-디히드로벤조푸란 유도체(2,3-dihydrobenzofuran derivative) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20140913 |